A Toast to the Last Decade and a Very Happy 2020 from Thrombosis and Haemostasis!

Gregory Y. H. Lip; Anne Rigby; Christian Weber

doi:10.1055/s-0039-3402054

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2020; 120(01): 001-004
DOI: 10.1055/s-0039-3402054

Editorial

Georg Thieme Verlag KG Stuttgart · New York

A Toast to the Last Decade and a Very Happy 2020 from Thrombosis and Haemostasis!

Gregory Y. H. Lip

¹Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom

²Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

,

Anne Rigby

³Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany

,

Christian Weber

³Institute for Cardiovascular Prevention (IPEK), LMU Munich, Munich, Germany

⁴German Centre for Cardiovascular Research (DZHK), partner site Munich Heart Alliance, Germany

⁵Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, the Netherlands

References
1 Lip GYH, Weber C. A happy new year from a 60-year-old journal ‘Thrombosis and Haemostasis’!. Thromb Haemost 2018; 118 (01) 1-3
2 Lip GYH, Weber C. Thrombosis and haemostasis wishes you a happy new year ahead!. Thromb Haemost 2019; 119 (01) 1-2
3 Weber C, Lip GYH. Editors' choice in the 60th anniversary year of thrombosis and haemostasis: past, present and future. Thromb Haemost 2018; 118 (01) 225-227
4 Weber C, Lip GYH. Thrombosis and haemostasis 2018 editor's choice papers. Thromb Haemost 2019; 119 (01) 183-186
5 Steffens S, Weber C. Immunotherapy for atherosclerosis-novel concepts. Thromb Haemost 2019; 119 (04) 515-516
6 Kaltner H, Gabius H-J. Sensing glycans as biochemical messages by tissue lectins: the sugar code at work in vascular biology. Thromb Haemost 2019; 119 (04) 517-533
7 Gencer S, van der Vorst EPC, Aslani M, Weber C, Döring Y, Duchene J. Atypical chemokine receptors in cardiovascular disease. Thromb Haemost 2019; 119 (04) 534-541
8 Van Avondt K, Maegdefessel L, Soehnlein O. Therapeutic targeting of neutrophil extracellular traps in atherogenic inflammation. Thromb Haemost 2019; 119 (04) 542-552
9 Sinitski D, Kontos C, Krammer C, Asare Y, Kapurniotu A, Bernhagen J. Macrophage migration inhibitory factor (MIF)-based therapeutic concepts in atherosclerosis and inflammation. Thromb Haemost 2019; 119 (04) 553-566
10 Guillamat-Prats R, Rami M, Herzig S, Steffens S. Endocannabinoid signalling in atherosclerosis and related metabolic complications. Thromb Haemost 2019; 119 (04) 567-575
11 Natarelli L, Weber C. Next-generation therapeutic concepts for atherosclerosis: focus on cell specificity and noncoding RNAs. Thromb Haemost 2019; 119 (08) 1199-1201
12 Paloschi V, Winter H, Viola J, Soehnlein O, Maegdefessel L. Mechanistic links between non-coding RNAs and myeloid cell inflammation in atherosclerosis. Thromb Haemost 2019; 119 (08) 1205-1211
13 Busygina K, Denzinger V, Bernlochner I, Weber C, Lorenz R, Siess W. Btk inhibitors as first oral atherothrombosis-selective antiplatelet drugs?. Thromb Haemost 2019; 119 (08) 1212-1221
14 Holdt LM, Kohlmaier A, Teupser D. Long noncoding RNAs of the arterial wall as therapeutic agents and targets in atherosclerosis. Thromb Haemost 2019; 119 (08) 1222-1236
15 Joppich M, Weber C, Zimmer R. Using context-sensitive text mining to identify mirnas in different stages of atherosclerosis. Thromb Haemost 2019; 119 (08) 1247-1264
16 Eckardt V, Weber C, von Hundelshausen P. Glycans and glycan-binding proteins in atherosclerosis. Thromb Haemost 2019; 119 (08) 1265-1273
17 Pircher J, Engelmann B, Massberg S, Schulz C. Platelet-neutrophil crosstalk in atherothrombosis. Thromb Haemost 2019; 119 (08) 1274-1282
18 Verheugt FWA. Platelets: the balance between aggregation and bleeding. Thromb Haemost 2019; 19 (10) 1553
19 Kaikita K, Hosokawa K, Dahlen JR, Tsujita K. Total thrombus-formation analysis system (T-TAS): clinical application of quantitative analysis of thrombus formation in cardiovascular disease. Thromb Haemost 2019; 19 (10) 1554-1562
20 Stojkovic S, Nossent AY, Haller P. , et al. MicroRNAs as regulators and biomarkers of platelet function and activity in coronary artery disease. Thromb Haemost 2019; 19 (10) 1563-1572
21 Schrör K, Kristensen SD, Storey RF, Verheugt FWA. Aspirin and primary prevention in patients with diabetes-a critical evaluation of available randomized trials and meta-analyses. Thromb Haemost 2019; 19 (10) 1573-1582
22 Sumaya W, Geisler T, Kristensen SD, Storey RF. Dual antiplatelet or dual antithrombotic therapy for secondary prevention in high-risk patients with stable coronary artery disease?. Thromb Haemost 2019; 19 (10) 1583-1589
23 Geisler T, Jorbenadze R, Popov A-F. , et al. Thrombogenicity and antithrombotic strategies in structural heart interventions and nonaortic cardiac device therapy-current evidence and practice. Thromb Haemost 2019; 19 (10) 1590-1605
24 Esteve-Pastor MA, Roldán V, Rivera-Caravaca JM, Ramírez-Macías I, Lip GYH, Marín F. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb Haemost 2019; 119 (12) 1901-1919
25 Ntaios G, Lip GYH. Stroke: insights into thromboembolism treatment and prevention through the decades. Thromb Haemost 2019; 119 (05) 685-687
26 Fiechter M, Haider A, Bengs S. , et al. Sex differences in the association between inflammation and ischemic heart disease. Thromb Haemost 2019; 119 (09) 1471-1480
27 Fanikos J, Murwin D, Gruenenfelder F. , et al. Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program. Thromb Haemost 2019; 120 (02) 27-35